NCT05222113View on ClinicalTrials.gov

OBSERVATIONAL STUDY OF COMPARISON EFFECTIVITY BETWEEN REMDESIVIR AND FAVIPIRAVIR IN SURABAYA, INDONESIA

CompletedOBSERVATIONAL
Enrollment

87

Participants

Timeline

Start Date

August 1, 2021

Primary Completion Date

September 25, 2021

Study Completion Date

September 25, 2021

Conditions
Duration of HospitalizationClinical Manifestation of COVID-19
Interventions
DRUG

Remdesivir

The patients, based on their clinical condition, got remdesivir OR favipiravir at least five days of treatment. The WHO ordinal scale was used to assess patients' clinical progress in the first and second weeks.

Trial Locations (1)

60119

Gotong Royong Surabaya Hospital, Surabaya

All Listed Sponsors
lead

Bernadette Dian Novita, MD.,PhD

OTHER

NCT05222113 - OBSERVATIONAL STUDY OF COMPARISON EFFECTIVITY BETWEEN REMDESIVIR AND FAVIPIRAVIR IN SURABAYA, INDONESIA | Biotech Hunter | Biotech Hunter